Continue Reading Post >

Latest Tweets

@BiotechTechAI Agree with both of you. Plus $AMRN #Vascepa has a market of 25% of the 38 million #Statin users who… https://t.co/hPrHChof65
16th October, 2018
@argoexp The beast is #Vascepa and people are catching on to REDUCE-IT and now EVAPORATE, the plaque regression stu… https://t.co/OzXLHI1PVD
16th October, 2018
$AMRN Amarin’s EVAPORATE is recruiting! Why would they start full speed on a plaque regression (holy grail) study i… https://t.co/sNM2LASuMh
16th October, 2018
$AMRN From ANCHOR trial, #Vascepa ⬇️ TG, non-HDL-C, VLDL-C, lipoprotein-associated phospholipase A2, Apo B, TC, VLD… https://t.co/RcssJBknlc
9th October, 2018
$AMRN VA proof of concept 150 patient study of #Vascepa in patients at risk of #Alzheimers underway. Hugely import… https://t.co/P1Bv4iEwX4
9th October, 2018
Dr. Christopher Cannon, MD, Professor of Medicine @harvardmed: #Vascepa, #REDUCE-IT Topline Results, and What’s Nex… https://t.co/n9ZylGlIJB
9th October, 2018
Dr. Christopher Cannon, MD: #Vascepa, #REDUCE-IT Topline Results, and What’s Next. https://t.co/hLgXo5sqQU @cpcannon
8th October, 2018